RHHBF - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD

Roche Holding AG

Grenzacherstrasse 124
Basel 4058
Switzerland
41 61 688 11 11
https://www.roche.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees103,613

Key executives

NameTitlePayExercisedYear born
Dr. Severin Schwan Ph.D.Exec. Chairman8.27MN/A1967
Dr. Thomas SchineckerChief Exec. Officer4.26MN/A1975
Dr. Alan HippeChief Financial & Information Officer4.52MN/A1967
Ms. Cristina A. WilburChief People Officer3.22MN/A1967
Dr. Johannes Carolus Clevers M.D., Ph.D.Head of Roche Pharma Research & Early Devel.90.83kN/A1957
Dr. Bruno EschliHead of Investor RelationsN/AN/AN/A
Ms. Claudia BockstiegelGen. CounselN/AN/A1964
Ms. Pascale SchmidtChief Compliance OfficerN/AN/A1973
Ms. Barbara SchadlerHead of Group CommunicationsN/AN/A1962
Dr. Nicolas DunantHead of Group Media RelationsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

Corporate governance

Roche Holding AG’s ISS governance QualityScore as of 1 June 2023 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.